Fresenius Medical Care (NYSE:FMS) Issues Quarterly Earnings Results

Fresenius Medical Care (NYSE:FMS) released its quarterly earnings results on Tuesday. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.07, Zacks reports. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $23.56 on Tuesday. The firm has a 50 day moving average of $23.39 and a 200-day moving average of $21.74. The company has a market cap of $13.83 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 52 week low of $17.93 and a 52 week high of $25.25.

Analyst Ratings Changes

FMS has been the subject of several recent research reports. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.